8:30 – 9:00

Welcoming face-to-face participants

9:00 – 9:15

Open ceremony
Frank VISSER, COO, ERBC Group, & Peter VESTBJERG, Head of International Sales, Ellegaard Göttingen Minipigs A/S

9:15- 9:30

A brief introduction to ERBC
Frank VISSER, COO, ERBC Group

9:30 - 10:15

The history of Göttingen Minipigs and their use in biomedical research
Peter VESTBJERG, Head of International Sales and Andres JENSEN, Study Director, Ellegaard Göttingen Minipigs A/S

10:15 - 11:00

Coffee break

11:00 - 11:45

Humanized Göttingen Minipigs for the toxicological testing of therapeutic antibodies
Antonio IGLESIAS, Consultant for Ellegaard Göttingen Minipigs A/S

11:45 - 12:30

Humanized Göttingen Minipigs: more predictive model for ADA or not?
Pascal CLAYETTE, Associate Scientific Director, Immunology & Virology and Cristina LONGOBARDI, Senior Study Director, ERBC Group

12:45 - 13:00

Small forum discussions – teasing questions/discussion

13:00 - 14:00

Lunch and posters session

14:00 - 15:30

Safety Pharmacology endpoints in Toxicity Sudies – 3R’s, including Göttingen Minipigs
Raafat FARES, Scientific Director, ERBC Group

Tolerance/Toxicity Sudies by Intravesical Instillation in Göttingen Minipigs; in-vivo observations and histopathology evaluation
Paola MINOSI, Study Director & Rosanna Manno, Senior Pathologist, ERBC Group

Neonatal study in piglets an animal model for intranasal pediatric drug delivery
Rosaria CICALESE, Associate Scientific director DART and Juvenile studies, ERBC Group

15:30 - 16:00

Q&A session

16:00 - 17:00

Closing ceremony: Frank VISSER & Peter VESTBJERG
Drinks ‘n’ Bites – post seminar discussion/interaction